Kotteas Elias A, Syrigos Konstantinos N, Saif Muhammad Wasif
Oncology Unit, Sotiria General Hospital, University of Athens, Athens, Greece.
Oncology Unit, Sotiria General Hospital, University of Athens, Athens, Greece; Thoracic Oncology Program, Yale School of Medicine, New Haven, CT, USA.
Onco Targets Ther. 2016 Feb 9;9:699-704. doi: 10.2147/OTT.S72155. eCollection 2016.
Neuroendocrine tumors are a rare and heterogeneous group of tumors with a variety of primary origins and variable aggressiveness. Platinum-based chemotherapy has been the cornerstone of treatment for the poorly differentiated tumors. However, well-differentiated neuroendocrine tumors are quite chemoresistant and therapy options are limited. Octreotide analogs and tyrosine kinase inhibitors are widely acceptable treatments due to substantial efficacy and tolerable toxicity. On the contrary, monotherapy or combinations of the only approved cytotoxic agent streptozocin with other drugs have been almost abandoned because of excessive toxic events. In recent years, the combination of capecitabine and temozolomide has emerged as the most promising and efficacious treatment. The oral route of administration and the substantial improvement in the outcomes with manageable toxicity are the major advantages. We reviewed the current literature and presented the profile of the capecitabine/temozolomide combination in the management of well-differentiated neuroendocrine tumors.
神经内分泌肿瘤是一组罕见且异质性的肿瘤，具有多种原发起源和不同的侵袭性。铂类化疗一直是低分化肿瘤治疗的基石。然而，高分化神经内分泌肿瘤具有相当的化疗耐药性，治疗选择有限。奥曲肽类似物和酪氨酸激酶抑制剂因其显著疗效和可耐受毒性而被广泛接受。相反，由于毒性过大，唯一获批的细胞毒性药物链脲佐菌素的单药治疗或与其他药物的联合治疗几乎已被摒弃。近年来，卡培他滨和替莫唑胺的联合治疗已成为最有前景且有效的治疗方法。口服给药途径以及毒性可控且疗效显著改善是其主要优势。我们回顾了当前文献，并介绍了卡培他滨/替莫唑胺联合治疗在高分化神经内分泌肿瘤管理中的概况。
